Wechselwirkung zwischen Darunavir und Ritonavir
Darunavir und Ritonavir: Beide FDA-Fachinformationen versehen diese Kombination mit den stärksten Formulierungen, etwa einer Gegenanzeige, einem umrahmten Warnhinweis (Boxed Warning) oder der Anweisung, sie zu vermeiden.
Nicht ohne ärztliche Anleitung kombinieren. Die unten zitierten Formulierungen der Fachinformation sind die stärksten, die die FDA verwendet.
Was die FDA-Fachinformationen sagen
Aus der FDA-Fachinformation zu Darunavir (PREZISTA) · Stand 2025-08-29
Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index).
Due to the need for co-administration of PREZISTA with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications.
…PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening…
PREZISTA/ritonavir is not recommended in pediatric patients below 3 years of age in view of toxicity and mortality observed in juvenile rats dosed with darunavir up to days 23 to 26 of age.
Not Recommended in Pediatric Patients Below 3 Years of Age PREZISTA/ritonavir in pediatric patients below 3 years of age is not recommended in view of toxicity and mortality observed in juvenile rats dosed with darunavir (from 20 mg/kg to 1000 mg/kg) up to days 23 to 26 of age [see Use in Specific Populations (8.1 and 8.4) and Clinical Pharmacology (12.3) ] .
Aus der FDA-Fachinformation zu Ritonavir (Norvir) · Stand 2026-07-23
When co-administering NORVIR with other protease inhibitors, see the full prescribing information for that protease inhibitor including important Warnings and Precautions.
Hepatotoxicity Hepatic transaminase elevations exceeding 5 times the upper limit of normal, clinical hepatitis, and jaundice have occurred in patients receiving NORVIR alone or in combination with other antiretroviral drugs (see Table 2).
Continued administration of ritonavir 600 mg twice daily following loss of viral suppression may increase the likelihood of cross-resistance to other protease inhibitors [see Microbiology ( 12.4 ) ] .
Titrate atorvastatin and rosuvastatin dose carefully and use the lowest necessary dose.If NORVIR is used with another protease inhibitor, see the complete prescribing information for the concomitant protease inhibitor for details on co-administration with atorvastatin and rosuvastatin.
…Interactions Concomitant Drug Class: Drug Name Effect on Concentration of Ritonavir or Concomitant Drug Clinical Comment HIV-Antiviral Agents HIV-1 Protease Inhibitor: atazanavir darunavir fosamprenavir ↑ amprenavir ↑ atazanavir ↑ darunavir See the complete prescribing information for fosamprenavir, atazanavir, darunavir for details on co-administration with…
Sie nehmen mehr als diese beiden ein? Wechselwirkungen summieren sich. Prüfen Sie Ihre gesamte Liste auf einmal; sie bleibt in Ihrem Browser.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Interaction Checker zitiert Texte aus FDA-Fachinformationen und NIH-Faktenblättern. Ob eine Wechselwirkung für Sie von Bedeutung ist, hängt von Dosierung, Einnahmezeitpunkt, Nieren- und Leberfunktion und weiteren Erkrankungen ab. Lassen Sie das in der Apotheke oder von Ihrer Ärztin bzw. Ihrem Arzt bestätigen.